On May 8, 2024, Pharming Group N.V. reported a 31% increase in first quarter revenues to $55.6 million, driven by the U.S. launch of Joenja® and growth of RUCONEST® revenues, reaching $46.0 million, an 8% rise compared to the previous year. The company remains on track for 2024 total revenue guidance of $280-$295 million.